Details of the Drug Reposition

General Information of This Drug (ID: DME9QGW)

Drug Name
Marizomib   DME9QGW
Synonyms
MARIZOMIB; salinosporamide A; 437742-34-2; (-)-Salinosporamide A; UNII-703P9YDP7F; NPI-0052; NPI 0052; ML 858; 703P9YDP7F; CHEBI:48045; (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-(1S)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; Marizomib [USAN:INN]; marizomibum; Marizomib (USAN/INN); Salinosporamide A (NPI-0052, Marizomib); SCHEMBL151667; CHEMBL371405; NGWSFRIPKNWYAO-SHTIJGAHSA-N; ZINC3990364; BDBM50398608; 2531AH; AKOS027323566; DB11762; Z-3093; D09640; 855517-10-1
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glioblastoma of brain DISESTHB 2A00.00 Phase 3 [1]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [2]
Multiple myeloma DISEWP9B 2A83 Phase 1 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03345095) A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (MIRAGE). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Triphase Accelerator .
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)